

Manakova or Lehtonen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4816093/publications.pdf>

Version: 2024-02-01

50
papers

1,991
citations

304743

22
h-index

265206

42
g-index

57
all docs

57
docs citations

57
times ranked

3115
citing authors

#	ARTICLE	IF	CITATIONS
1	PSEN1 Mutant iPSC-Derived Model Reveals Severe Astrocyte Pathology in Alzheimer's Disease. <i>Stem Cell Reports</i> , 2017, 9, 1885-1897.	4.8	239
2	PSEN1 ^{E9} , APP ^{swe} , and APOE4 Confer Disparate Phenotypes in Human iPSC-Derived Microglia. <i>Stem Cell Reports</i> , 2019, 13, 669-683.	4.8	132
3	Nrf2 Regulates Neurogenesis and Protects Neural Progenitor Cells Against A β Toxicity. <i>Stem Cells</i> , 2014, 32, 1904-1916.	3.2	110
4	Structural Immaturity of Human iPSC-Derived Cardiomyocytes: In Silico Investigation of Effects on Function and Disease Modeling. <i>Frontiers in Physiology</i> , 2018, 9, 80.	2.8	110
5	Immunomodulation by interleukin-33 is protective in stroke through modulation of inflammation. <i>Brain, Behavior, and Immunity</i> , 2015, 49, 322-336.	4.1	107
6	Interleukin-33 treatment reduces secondary injury and improves functional recovery after contusion spinal cord injury. <i>Brain, Behavior, and Immunity</i> , 2015, 44, 68-81.	4.1	105
7	Metabolic alterations in Parkinson's disease astrocytes. <i>Scientific Reports</i> , 2020, 10, 14474.	3.3	104
8	Dysfunction of Cellular Proteostasis in Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2019, 13, 457.	2.8	95
9	Astrocyte alterations in neurodegenerative pathologies and their modeling in human induced pluripotent stem cell platforms. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 2739-2760.	5.4	88
10	Creation of a library of induced pluripotent stem cells from Parkinsonian patients. <i>Npj Parkinson's Disease</i> , 2016, 2, 16009.	5.3	74
11	Altered Brain Endothelial Cell Phenotype from a Familial Alzheimer Mutation and Its Potential Implications for Amyloid Clearance and Drug Delivery. <i>Stem Cell Reports</i> , 2020, 14, 924-939.	4.8	63
12	Aflatoxin B1 a potential endocrine disruptor up-regulates CYP19A1 in JEG-3 cells. <i>Toxicology Letters</i> , 2011, 202, 161-167.	0.8	50
13	Microglia-like Cells Promote Neuronal Functions in Cerebral Organoids. <i>Cells</i> , 2022, 11, 124.	4.1	50
14	Microglial amyloid beta clearance is driven by PIEZO1 channels. <i>Journal of Neuroinflammation</i> , 2022, 19, .	7.2	45
15	Lack of robust protective effect of quercetin in two types of 6-hydroxydopamine-induced parkinsonian models in rats and dopaminergic cell cultures. <i>Brain Research</i> , 2008, 1203, 149-159.	2.2	42
16	Sex-specific transcriptional and proteomic signatures in schizophrenia. <i>Nature Communications</i> , 2019, 10, 3933.	12.8	41
17	Transplanted Human Induced Pluripotent Stem Cell-Derived Neural Progenitor Cells Do Not Promote Functional Recovery of Pharmacologically Immunosuppressed Mice with Contusion Spinal Cord Injury. <i>Cell Transplantation</i> , 2015, 24, 1799-1812.	2.5	40
18	Pyrrolidine dithiocarbamate activates the Nrf2 pathway in astrocytes. <i>Journal of Neuroinflammation</i> , 2016, 13, 49.	7.2	38

#	ARTICLE	IF	CITATIONS
19	Bloodâ€‘Brain Barrier and Neurodegenerative Diseasesâ€‘ Modeling with iPSC-Derived Brain Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7710.	4.1	36
20	A prolyl oligopeptidase inhibitor, Z-Pro-Prolinal, inhibits glyceraldehyde-3-phosphate dehydrogenase translocation and production of reactive oxygen species in CV1-P cells exposed to 6-hydroxydopamine. <i>Toxicology in Vitro</i> , 2006, 20, 1446-1454.	2.4	32
21	NFâ€‘E2â€‘related factor 2 activation boosts antioxidant defenses and ameliorates inflammatory and amyloid properties in human Presenilinâ€‘1 mutated Alzheimer's disease astrocytes. <i>Glia</i> , 2020, 68, 589-599.	4.9	27
22	Production of monocytic cells from bone marrow stem cells: therapeutic usage in Alzheimerâ€‘s disease. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 1060-1073.	3.6	26
23	Inhibition of Excessive Oxidative Protein Folding Is Protective in MPP⁺ Toxicity-Induced Parkinson's Disease Models. <i>Antioxidants and Redox Signaling</i> , 2016, 25, 485-497.	5.4	26
24	Proteostasis Disturbances and Inflammation in Neurodegenerative Diseases. <i>Cells</i> , 2020, 9, 2183.	4.1	26
25	ADAMTS-4 promotes neurodegeneration in a mouse model of amyotrophic lateral sclerosis. <i>Molecular Neurodegeneration</i> , 2016, 11, 10.	10.8	25
26	The iPSC perspective on schizophrenia. <i>Trends in Neurosciences</i> , 2022, 45, 8-26.	8.6	24
27	Different viabilities and toxicity types after 6-OHDA and Ara-C exposure evaluated by four assays in five cell lines. <i>Toxicology in Vitro</i> , 2008, 22, 182-189.	2.4	22
28	Neurobiological roots of psychopathy. <i>Molecular Psychiatry</i> , 2020, 25, 3432-3441.	7.9	21
29	The roles of dopamine transporter and Bcl-2 protein in the protection of CV1-P cells from 6-OHDA-induced toxicity. <i>Toxicology Letters</i> , 2004, 154, 117-123.	0.8	20
30	An arylthiazine derivative is a potent inhibitor of lipid peroxidation and ferroptosis providing neuroprotection in vitro and in vivo. <i>Scientific Reports</i> , 2021, 11, 3518.	3.3	20
31	Long-term interleukin-33 treatment delays disease onset and alleviates astrocytic activation in a transgenic mouse model of amyotrophic lateral sclerosis. <i>IBRO Reports</i> , 2019, 6, 74-86.	0.3	18
32	A CX3CR1 Reporter hESC Line Facilitates Integrative Analysis of In-Vitro-Derived Microglia and Improved Microglia Identity upon Neuron-Glia Co-culture. <i>Stem Cell Reports</i> , 2020, 14, 1018-1032.	4.8	16
33	Failure of FK506 (tacrolimus) to alleviate apomorphine-induced circling in rat Parkinson model in spite of some cytoprotective effects in SH-SY5Y dopaminergic cells. <i>Brain Research</i> , 2005, 1038, 83-91.	2.2	14
34	Utilising Induced Pluripotent Stem Cells in Neurodegenerative Disease Research: Focus on Glia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4334.	4.1	14
35	Molecular signaling pathways underlying schizophrenia. <i>Schizophrenia Research</i> , 2021, 232, 33-41.	2.0	14
36	Contribution of astrocytes to familial risk and clinical manifestation of schizophrenia. <i>Glia</i> , 2022, 70, 650-660.	4.9	12

#	ARTICLE	IF	CITATIONS
37	CNS Redox Homeostasis and Dysfunction in Neurodegenerative Diseases. <i>Antioxidants</i> , 2022, 11, 405.	5.1	11
38	Generation of a human induced pluripotent stem cell line from a patient with a rare A673T variant in amyloid precursor protein gene that reduces the risk for Alzheimer's disease. <i>Stem Cell Research</i> , 2018, 30, 96-99.	0.7	9
39	Increased p53 levels without caspase-3 activity and change of cell viability in 6-hydroxydopamine-treated CV1-P cells. <i>Cell Biology and Toxicology</i> , 2003, 19, 177-187.	5.3	8
40	Generation of a human induced pluripotent stem cell line (LL008 1.4) from a familial Alzheimer's disease patient carrying a double KM670/671NL (Swedish) mutation in APP gene. <i>Stem Cell Research</i> , 2018, 31, 181-185.	0.7	7
41	Metabolic and immune dysfunction of glia in neurodegenerative disorders: Focus on iPSC models. <i>Stem Cells</i> , 2021, 39, 256-265.	3.2	7
42	Generation of a human induced pluripotent stem cell line (UEFi003-A) carrying heterozygous A673T variant in amyloid precursor protein associated with a reduced risk of Alzheimer's disease. <i>Stem Cell Research</i> , 2020, 48, 101968.	0.7	5
43	Microglia Orchestrate Neuronal Activity in Brain Organoids. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
44	Expression of tyrosine hydroxylase in the striatum of atipamezole-treated rats. <i>European Journal of Pharmaceutical Sciences</i> , 2009, 36, 602-604.	4.0	1
45	Nontargeted Metabolite Profiling of Induced Pluripotent Stem Cells (iPSCs) Derived Neural Cells: Insights Into Mechanisms of Brain Diseases. , 0, , .		0
46	O7.7. NEUROBIOLOGICAL ROOTS OF SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2019, 45, S182-S182.	4.3	0
47	Studying non-cell-autonomous neurodegeneration in Parkinson's disease with induced pluripotent stem cells. , 2021, , 251-276.		0
48	Tyrosine hydroxylase gene transfections to different sites of striatum in the rat model of Parkinson's disease. <i>Open Journal of Genetics</i> , 2013, 03, 30-37.	0.1	0
49	[P3 ¹⁷⁰]: HUMAN IPSC-DERIVED ALZHEIMER'S DISEASE ASTROCYTES RECAPITULATE DISEASE-RELATED PHENOTYPES. <i>Alzheimer's and Dementia</i> , 2017, 13, P999.	0.8	0
50	Identification of mechanisms leading to blood-brain barrier dysfunction in Parkinson's disease. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO4-1-124.	0.0	0